XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.22.4

Supplementary Balance Sheet Information | 12 Months Ended
--- | ---
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Supplementary Balance Sheet Information | Supplementary Balance Sheet Information Short-term investments available-for-sale securities consist of the following:
| As of December 31, 2022
(in thousands) | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Fair Market Value
Maturity less than 1 year: |  |  |  |  |  |  |
Certificate of deposit | $ | 16,101 |  |  | $ | 3 |  |  | $ | (81) |  |  | $ | 16,023 |
Corporate debt securities | 44,806 |  |  | 8 |  |  | (275) |  |  | 44,539 |
Commercial paper | 13,203 |  |  | 4 |  |  | (20) |  |  | 13,187 |
U.S. government agencies | 2,284 |  |  | 4 |  |  | — |  |  | 2,288 |
U.S. treasury securities | 7,905 |  |  | — |  |  | (18) |  |  | 7,887 |
Total maturity less than 1 year | 84,299 |  |  | 19 |  |  | (394) |  |  | 83,924 |
Maturity 1 to 2 years: |  |  |  |  |  |  |
Corporate debt securities | 5,016 |  |  | 1 |  |  | (21) |  |  | 4,996 |
Total maturity 1 to 2 years | 5,016 |  |  | 1 |  |  | (21) |  |  | 4,996 |
Total short-term investments | $ | 89,315 |  |  | $ | 20 |  |  | $ | (415) |  |  | $ | 88,920 |
| As of December 31, 2021
(in thousands) | Amortized Cost |  | Gross Unrealized Gains |  | Gross Unrealized Losses |  | Fair Market Value
Maturity less than 1 year: |  |  |  |  |  |  |
Certificate of deposit | $ | 1,260 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,260 |
Corporate debt securities | 58,822 |  |  | 2 |  |  | (38) |  |  | 58,786 |
Commercial paper | 14,453 |  |  | 4 |  |  | (3) |  |  | 14,454 |
Non U.S. government | 728 |  |  | — |  |  | — |  |  | 728 |
U.S. treasury securities | 20,380 |  |  | — |  |  | (24) |  |  | 20,356 |
Total maturity less than 1 year | 95,643 |  |  | 6 |  |  | (65) |  |  | 95,584 |
Maturity 1 to 2 years: |  |  |  |  |  |  |
Corporate debt securities | 29,676 |  |  | 1 |  |  | (73) |  |  | 29,604 |
U.S. treasury securities | 3,701 |  |  | — |  |  | (11) |  |  | 3,690 |
Total maturity 1 to 2 years | 33,377 |  |  | 1 |  |  | (84) |  |  | 33,294 |
Total short-term investments | $ | 129,020 |  |  | $ | 7 |  |  | $ | (149) |  |  | $ | 128,878 |
For the year ended December 31, 2022 the net realized loss recorded within the Company's statement of operations from the sale of short-term investments was $0.2 million. The amount of gains and losses reclassified out of other comprehensive income for the period related to the sales of short-term investments was not material for the year ended December 31, 2022. Unrealized losses in investments available for sale debt securities at December 31, 2022, were primarily due to increases in interest rates, not due to increased credit risks associated with specific securities. It is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:
| As of December 31, 2022
(in thousands) | Fair Market Value |  | Gross Unrealized Loss
Corporate debt securities | $ | 17,084 |  |  | $ | (161) |
U.S. treasury securities | 3,666 |  |  | (14) |
Total short-term investments | $ | 20,750 |  |  | $ | (175) |
Property and Equipment Fixed assets consist of furniture and office equipment, leasehold improvements and laboratory equipment. Depreciation expense for property and equipment for the years ended December 31, 2022 and 2021 was $0.2 million and $0.5 million, respectively. Property and equipment consisted of the following:
| As of December 31,
(in thousands) | 2022 |  | 2021
Furniture and office equipment | $ | 1,066 |  |  | $ | 955 |
Leasehold improvements | 2,560 |  |  | 1,962 |
Laboratory equipment | 1,056 |  |  | 906 |
| 4,682 |  |  | 3,823 |
Less—accumulated depreciation | (3,413) |  |  | (3,441) |
Property and equipment, net | $ | 1,269 |  |  | $ | 382 |
Accrued Liabilities Accrued liabilities consisted of the following:
| As of December 31,
(in thousands) | 2022 |  | 2021
Accrued compensation | $ | 1,849 |  |  | $ | 1,435 |
Preferred stock dividend(1) | — |  |  | 414 |
Clinical trials | 2,333 |  |  | 1,639 |
Research agreements and services | 509 |  |  | 726 |
Director fees | 125 |  |  | 141 |
Patent, license and other fees | 24 |  |  | 43 |
Other accrued liabilities | 337 |  |  | 129 |
Total accrued liabilities | $ | 5,177 |  |  | $ | 4,527 |
(1)See Note 2 to the financial statements.

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI https://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration